Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005365 | 0.91 | CACNA2D1 (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4014167 | 0.89 | CACNA2D1 (0.54) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4007045 | 0.88 | CACNA2D1 (0.38) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4008983 | 0.84 | CACNA2D1 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4011300 | 0.84 | CACNA2D1 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4014259 | 0.82 | CACNA2D1 (0.38) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4013614 | 0.81 | CACNA2D1 (0.39) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4011306 | 0.77 | ALDH1A1 (0.31) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4007050 | 0.76 | CACNA2D1 (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4008800 | 0.76 | CACNA2D1 (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | claimed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | claimed |
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CACNA2D1 40/4885CACNB3 77/4885CACNA1C 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.